News Kite and Fosun appoint leader for CAR-T debut in China But rival Juno finally gives up on lead therapy.
News Next gen psoriasis drugs show superiority to Stelara Guselkumab can also be used if older drug Stellara fails.
Views & Analysis Interview: Vas Narasimhan on Novartis' goal to lead in CAR-T... Novartis’ head of drug development talks about its stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions about safety, manufacturing and cost versus clinical value remain
Views & Analysis Orphan drugs will fuel pharma's future - and a pricing pushb... Evaluate predicts sales could approach $8bn if approved.
Events Partner Content Viral Safety - 25-27 April 2017 - Amserdam, The Netherlands Viral Safety conference
News EU green light for Novartis combo in lung cancer Tafinlar and Mekinist looks set for approval in BRAF V600 lung cancer
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
